Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease…Currently Enrolling

A Randomized, Placebo controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease. (Prodromal AD)

This is an 18 month study in which subjects that screen and qualify will go onto the program taking the investigation medication by mouth once daily.

Mild to Moderate Alzheimer’s Disease Treated with Donepezil…Ongoing Study

Randomized, double-blind, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with Donepezil.

This is a 28 week study in which qualified participants will take the investigational medication or placebo ( a dummy capsule without an active ingredient ) once daily by mouth.

Potential patients must have been receiving a drug containing Donepezil for the last 6 months,